Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > New Milestone List - or lack of.....
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1374)
•••
Comment by Pandoraon Jul 12, 2021 4:40pm
157 Views
Post# 33531008

RE:New Milestone List - or lack of.....

RE:New Milestone List - or lack of.....
Pareto8020 wrote: Well they just completely obliterated the upcoming Milestones timelines in the new July Investor Presentation.  And what is this get feedback on Phase I analysis?  Get it done for crying out loud - screw feedback!  What kind of Mickey Mouse contract did they sign?  Feedback?  How about results Howard!!!

https://www.sironabiochem.com/wp-content/uploads/2021/07/SBM-Investor-Presentation-July2021.pdf

Sirona is working intensively towards achieving the following milestones:* • Establish terms with global pharma company for rights to TFC-1067 • Establish terms with new organization in China for TFC-1067 • Receive terms for additional licensing agreement for the SGLT2 inhibitor in new markets • Secure non-dilutive funding through anticipated collaborations • Receive feedback on analysis from Phase I (from Wanbang) for the SGLT2 inhibitor • Complete safety studies for anti-aging compound in preparation for clinical study • Establish detailed project plan for scale-up and clinical trial • Enter clinical trial for anti-wrinkle compound • Advance the anti-viral compounds into preclinical studies


in·ten·sive·ly
 
adverb
wi "with extreme concentration or effort; very thoroughly or vigorously".
    
     "in a way that involves a lot of effort or activity in a short period of time".





 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities